# A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

> **NCT00463606** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 760 (actual)

## Conditions studied

- Hypercholesterolemia
- Dyslipidemia

## Interventions

- **DRUG:** ABT-335 and rosuvastatin calcium
- **DRUG:** ABT-335
- **DRUG:** rosuvastatin calcium

## Key facts

- **NCT ID:** NCT00463606
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 760 (ACTUAL)
- **Last updated:** 2012-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00463606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00463606, "A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00463606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*